Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection.
| dc.contributor.author | Yang, H | |
| dc.contributor.author | Wu, H | |
| dc.contributor.author | Hancock, G | |
| dc.contributor.author | Clutton, G | |
| dc.contributor.author | Sande, N | |
| dc.contributor.author | Xu, X | |
| dc.contributor.author | Yan, H | |
| dc.contributor.author | Huang, X | |
| dc.contributor.author | Angus, B | |
| dc.contributor.author | Kuldanek, K | |
| dc.contributor.author | Fidler, S | |
| dc.contributor.author | Denny, TN | |
| dc.contributor.author | Birks, J | |
| dc.contributor.author | McMichael, A | |
| dc.contributor.author | Dorrell, L | |
| dc.coverage.spatial | United States | |
| dc.date.accessioned | 2017-06-02T12:31:23Z | |
| dc.date.available | 2017-06-02T12:31:23Z | |
| dc.date.issued | 2012-08-15 | |
| dc.description.abstract | BACKGROUND: Rare human immunodeficiency virus type 1 (HIV-1)-infected individuals who maintain control of viremia without therapy show potent CD8+ T-cell-mediated suppression of viral replication in vitro. Whether this is a determinant of the rate of disease progression in viremic individuals is unknown. METHODS: We measured CD8+ T-cell-mediated inhibition of a heterologous HIV-1 isolate in 50 HIV-1-seropositive adults with diverse progression rates. Linear mixed models were used to determine whether CD8+ T-cell function could explain variation in the rate of CD4+ T-cell decline. RESULTS: There was a significant interaction between CD8+ T-cell antiviral activity in vitro and the rate of CD4+ T-cell decline in chronically infected individuals (P < .0001). In a second prospective analysis of recently infected subjects followed for up to 3 years, CD8+ T-cell antiviral activity strongly predicted subsequent CD4+ T-cell decline (P < .0001) and explained up to 73% of the interindividual variation in the CD4+ T-cell slope. In addition, it was inversely associated with viral load set point (r = -0.68 and P = .002). CONCLUSIONS: The antiviral inhibitory capacity of CD8+ T cells is highly predictive of CD4+ T-cell loss in early HIV-1 infection. It has potential as a benchmark of effective immunity in vaccine evaluation. | |
| dc.identifier | ||
| dc.identifier | jis379 | |
| dc.identifier.eissn | 1537-6613 | |
| dc.identifier.uri | ||
| dc.language | eng | |
| dc.publisher | Oxford University Press (OUP) | |
| dc.relation.ispartof | J Infect Dis | |
| dc.relation.isversionof | 10.1093/infdis/jis379 | |
| dc.subject | Adult | |
| dc.subject | Biomarkers | |
| dc.subject | CD4 Lymphocyte Count | |
| dc.subject | CD8-Positive T-Lymphocytes | |
| dc.subject | Female | |
| dc.subject | HIV Infections | |
| dc.subject | HIV-1 | |
| dc.subject | Humans | |
| dc.subject | Male | |
| dc.subject | Middle Aged | |
| dc.subject | Prognosis | |
| dc.title | Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. | |
| dc.type | Journal article | |
| pubs.author-url | ||
| pubs.begin-page | 552 | |
| pubs.end-page | 561 | |
| pubs.issue | 4 | |
| pubs.organisational-group | Clinical Science Departments | |
| pubs.organisational-group | Duke | |
| pubs.organisational-group | Duke Human Vaccine Institute | |
| pubs.organisational-group | Institutes and Centers | |
| pubs.organisational-group | Medicine | |
| pubs.organisational-group | Medicine, Duke Human Vaccine Institute | |
| pubs.organisational-group | School of Medicine | |
| pubs.publication-status | Published | |
| pubs.volume | 206 |